Biomarkers for other immunotherapeutic strategies are more advanced, for example, patients who responded to combination T-VEC and anti-PD-1 had elevated CD8+ T cells, PD-L1, and IFNγ gene expression [10]; however, response did not appear to be associated with baseline tumour CD8+ T cells or IFNγ signature. Here, CD8A is linked to neoplasm.